Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.

The development of safe and effective vaccines against both bovine and human respiratory syncytial viruses (BRSV, HRSV) to be used in the presence of RSV-specific maternally-derived antibodies (MDA) remains a high priority in human and veterinary medicine. Herein, we present safety and efficacy resu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Krister Blodörn, Sara Hägglund, Jenna Fix, Catherine Dubuquoy, Boby Makabi-Panzu, Michelle Thom, Per Karlsson, Jean-Louis Roque, Erika Karlstam, John Pringle, Jean-François Eléouët, Sabine Riffault, Geraldine Taylor, Jean François Valarcher
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ee5dbf2882934f13b2c98eaea6b2fee4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ee5dbf2882934f13b2c98eaea6b2fee4
record_format	dspace
spelling	oai:doaj.org-article:ee5dbf2882934f13b2c98eaea6b2fee42021-11-18T08:15:02ZVaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.1932-620310.1371/journal.pone.0100392https://doaj.org/article/ee5dbf2882934f13b2c98eaea6b2fee42014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24945377/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203The development of safe and effective vaccines against both bovine and human respiratory syncytial viruses (BRSV, HRSV) to be used in the presence of RSV-specific maternally-derived antibodies (MDA) remains a high priority in human and veterinary medicine. Herein, we present safety and efficacy results from a virulent BRSV challenge of calves with MDA, which were immunized with one of three vaccine candidates that allow serological differentiation of infected from vaccinated animals (DIVA): an SH gene-deleted recombinant BRSV (ΔSHrBRSV), and two subunit (SU) formulations based on HRSV-P, -M2-1, and -N recombinant proteins displaying BRSV-F and -G epitopes, adjuvanted by either oil emulsion (Montanide ISA71VG, SUMont) or immunostimulating complex matrices (AbISCO-300, SUAbis). Whereas all control animals developed severe respiratory disease and shed high levels of virus following BRSV challenge, ΔSHrBRSV-immunized calves demonstrated almost complete clinical and virological protection five weeks after a single intranasal vaccination. Although mucosal vaccination with ΔSHrBRSV failed to induce a detectable immunological response, there was a rapid and strong anamnestic mucosal BRSV-specific IgA, virus neutralizing antibody and local T cell response following challenge with virulent BRSV. Calves immunized twice intramuscularly, three weeks apart with SUMont were also well protected two weeks after boost. The protection was not as pronounced as that in ΔSHrBRSV-immunized animals, but superior to those immunized twice subcutaneously three weeks apart with SUAbis. Antibody responses induced by the subunit vaccines were non-neutralizing and not directed against BRSV F or G proteins. When formulated as SUMont but not as SUAbis, the HRSV N, P and M2-1 proteins induced strong systemic cross-protective cell-mediated immune responses detectable already after priming. ΔSHrBRSV and SUMont are two promising DIVA-compatible vaccines, apparently inducing protection by different immune responses that were influenced by vaccine-composition, immunization route and regimen.Krister BlodörnSara HägglundJenna FixCatherine DubuquoyBoby Makabi-PanzuMichelle ThomPer KarlssonJean-Louis RoqueErika KarlstamJohn PringleJean-François EléouëtSabine RiffaultGeraldine TaylorJean François ValarcherPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 6, p e100392 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Krister Blodörn Sara Hägglund Jenna Fix Catherine Dubuquoy Boby Makabi-Panzu Michelle Thom Per Karlsson Jean-Louis Roque Erika Karlstam John Pringle Jean-François Eléouët Sabine Riffault Geraldine Taylor Jean François Valarcher Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.
description	The development of safe and effective vaccines against both bovine and human respiratory syncytial viruses (BRSV, HRSV) to be used in the presence of RSV-specific maternally-derived antibodies (MDA) remains a high priority in human and veterinary medicine. Herein, we present safety and efficacy results from a virulent BRSV challenge of calves with MDA, which were immunized with one of three vaccine candidates that allow serological differentiation of infected from vaccinated animals (DIVA): an SH gene-deleted recombinant BRSV (ΔSHrBRSV), and two subunit (SU) formulations based on HRSV-P, -M2-1, and -N recombinant proteins displaying BRSV-F and -G epitopes, adjuvanted by either oil emulsion (Montanide ISA71VG, SUMont) or immunostimulating complex matrices (AbISCO-300, SUAbis). Whereas all control animals developed severe respiratory disease and shed high levels of virus following BRSV challenge, ΔSHrBRSV-immunized calves demonstrated almost complete clinical and virological protection five weeks after a single intranasal vaccination. Although mucosal vaccination with ΔSHrBRSV failed to induce a detectable immunological response, there was a rapid and strong anamnestic mucosal BRSV-specific IgA, virus neutralizing antibody and local T cell response following challenge with virulent BRSV. Calves immunized twice intramuscularly, three weeks apart with SUMont were also well protected two weeks after boost. The protection was not as pronounced as that in ΔSHrBRSV-immunized animals, but superior to those immunized twice subcutaneously three weeks apart with SUAbis. Antibody responses induced by the subunit vaccines were non-neutralizing and not directed against BRSV F or G proteins. When formulated as SUMont but not as SUAbis, the HRSV N, P and M2-1 proteins induced strong systemic cross-protective cell-mediated immune responses detectable already after priming. ΔSHrBRSV and SUMont are two promising DIVA-compatible vaccines, apparently inducing protection by different immune responses that were influenced by vaccine-composition, immunization route and regimen.
format	article
author	Krister Blodörn Sara Hägglund Jenna Fix Catherine Dubuquoy Boby Makabi-Panzu Michelle Thom Per Karlsson Jean-Louis Roque Erika Karlstam John Pringle Jean-François Eléouët Sabine Riffault Geraldine Taylor Jean François Valarcher
author_facet	Krister Blodörn Sara Hägglund Jenna Fix Catherine Dubuquoy Boby Makabi-Panzu Michelle Thom Per Karlsson Jean-Louis Roque Erika Karlstam John Pringle Jean-François Eléouët Sabine Riffault Geraldine Taylor Jean François Valarcher
author_sort	Krister Blodörn
title	Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.
title_short	Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.
title_full	Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.
title_fullStr	Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.
title_full_unstemmed	Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.
title_sort	vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (brsv) with deletion of the sh gene and subunit vaccines based on recombinant human rsv proteins: n-nanorings, p and m2-1, in calves with maternal antibodies.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/ee5dbf2882934f13b2c98eaea6b2fee4
work_keys_str_mv	AT kristerblodorn vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT sarahagglund vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT jennafix vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT catherinedubuquoy vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT bobymakabipanzu vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT michellethom vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT perkarlsson vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT jeanlouisroque vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT erikakarlstam vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT johnpringle vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT jeanfrancoiseleouet vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT sabineriffault vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT geraldinetaylor vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies AT jeanfrancoisvalarcher vaccinesafetyandefficacyevaluationofarecombinantbovinerespiratorysyncytialvirusbrsvwithdeletionoftheshgeneandsubunitvaccinesbasedonrecombinanthumanrsvproteinsnnanoringspandm21incalveswithmaternalantibodies
_version_	1718422019898343424

Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.

Ejemplares similares